Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4423900 | 0.91 | TLR7 (0.57) | TLR7NUDT1 | |
| SCHEMBL2060346 | 0.91 | TLR7 (0.65) | TLR7 | |
| SCHEMBL21449008 | 0.89 | TLR7 (0.51) | TLR7 | |
| SCHEMBL31126376 | 0.89 | TLR7 (0.59) | TLR7NUDT1 | |
| SCHEMBL4425489 | 0.89 | TLR7 (0.59) | TLR7NUDT1 | |
| SCHEMBL4134546 | 0.88 | TLR7 (0.60) | TLR7NUDT1 | |
| SCHEMBL510344 | 0.87 | TLR7 (0.74) | TLR7NUDT1 | |
| SCHEMBL21449093 | 0.86 | TLR7 (0.61) | TLR7NUDT1 | |
| SCHEMBL4128956 | 0.86 | TLR7 (0.61) | TLR7NUDT1 | |
| SCHEMBL7211538 | 0.85 | TLR7 (0.60) | TLR7NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903987-B1 | PHOSPHOLIPID DRUG ANALOGS | UROGEN PHARMA LTD (IL) | 2017-09-20 | — | — | EP | disclosed |
| US-9540407-B2 | Phospholipid drug analogs | UROGEN PHARMA LTD (IL) | 2017-01-10 | — | — | US | disclosed |
| US-9540407-B2 | Phospholipid drug analogs | UROGEN PHARMA LTD (IL) | 2017-01-10 | — | — | US | disclosed |
| EP-2563404-B1 | PHOSPHOLIPID DRUG ANALOGS | UROGEN PHARMA LTD (IL) | 2016-09-21 | — | — | EP | disclosed |
| US-20160090395-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2016-03-31 | — | — | US | disclosed |
| US-20160090395-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2016-03-31 | — | — | US | disclosed |
| US-9180183-B2 | Phospholipid drug analogs | TELORMEDIX SA (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9180183-B2 | Phospholipid drug analogs | TELORMEDIX SA (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9173936-B2 | Phospholipid drug analogs | TELORMEDIX SA (CH) | 2015-11-03 | — | — | US | disclosed |
| US-9173935-B2 | Phospholipid drug analogs | TELORMEDIX SA (CH) | 2015-11-03 | — | — | US | disclosed |
| EP-2510946-A1 | Conjugates of synthetic tlr agonists and uses therefor | The Regents of The University of California (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20120148660-A1 | CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO UCSD TECHNOLOGY TRANSFER OFFICE (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120009247-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120009247-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120003298-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE | TELORMEDIX SA (CH) | 2012-01-05 | — | — | US | disclosed |
| US-20120003298-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE | TELORMEDIX SA (CH) | 2012-01-05 | — | — | US | disclosed |
| WO-2011134669-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE | TELORMEDIX SA (CH) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011134668-A1 | PHOSPHOLIPID DRUG ANALOGS | TELORMEDIX SA (CH) | 2011-11-03 | — | — | WO | disclosed |
| EP-2125007-A2 | CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR | Regents of the University of California (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008115319-A2 | CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003298-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE | CD4, IL4, CCR4 | TLR7 20/4885NUDT1 3462/4885 |
| US-20120148660-A1 | CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR | TLR1, TLR5, TLR8 | TLR7 4/4885NUDT1 2757/4885 |
| US-20160090395-A1 | PHOSPHOLIPID DRUG ANALOGS | PHOSPHO1, PXMP4, SGMS1 | TLR7 1935/4885NUDT1 1425/4885 |
| US-20120009247-A1 | PHOSPHOLIPID DRUG ANALOGS | PHOSPHO1, PXMP4, SGMS1 | TLR7 1935/4885NUDT1 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.